Greater preference and better satisfaction with alendronate 70 mg weekly versus alendronate 10 daily for the treatment of postmenopausal osteoporosis
Journal Title: Przegląd Menopauzalny - Year 2005, Vol 22, Issue 6
Abstract
In the treatment of osteoporosis one or more medications must be taken at least once daily for many years. The goal of the study was to assess the factors that influence the preference for medication both of the patients and the doctors, and patients' adherence to suggestions of their doctors. Also satisfaction with the treatment of the women in the selected osteoporotic population and influence of educational program on patients and doctors cooperation in the treatment process have been investigated. It was observed that the doctors order medications taking into account their efficiency, safety, convenience of usage and the price. The same criteria affect the patients choice. The patients prefer the treatment with alendronate 70 mg as it is more convenient. They are more satisfied with once a week dosage of medication. The patients who are educated about osteoporosis are less willing to give up the treatment with alendronate 70mg than alendronate 10mg. The side effects occur less frequently while taking alendronate 70 mg once a week than alendronate 10 mg once daily. We concluded that the preference and satisfaction with the treatment of osteoporosis are strongly greater for "once a week" manner of alendronate dosage than taking of medication every day.
Authors and Affiliations
Andrzej Sawicki
Keywords
Related Articles
- EP ID EP159778
- DOI -
- Views 63
- Downloads 0
Progress in ovarian cancer diagnostics
Ovarian cancer is characterized by lack of early symptoms, presentation at an advanced stage, and poor prognosis. The molecular events leading to the development and progression of ovarian carcinoma are not completely...
Analysis of complications after operations with use of IVS tapes used for stress urinary incontinence treatment
Aim of the study: The aim of the study was analysis of complications which occurred during and after IVS operations, which were performed in Clinic of Gynecology and Gynecologic Oncology, I Department of Gynecology and...
Wpływ hormonalnej terapii zastępczej stosowanej w monoterapii lub w terapii skojarzonej z alendronianem na gęstość mineralną kości u pacjentek z osteoporozą
Wstęp: Hormonalna terapia zastępcza i bisfosfoniany są uznanymi formami terapii osteoporozy. Jednak przewaga terapii skojarzonej z zastosowaniem obu grup leków równocześnie nie do końca jest dobrze udokumentowana. Cel...
Późne macierzyństwo – przebieg ciąży i porodu powyżej 35. roku życia
Cel pracy: Celem pracy było określenie czynników ryzyka ciąży i porodu u ciężarnych i rodzących po 35. roku życia. Materiał i metody: Badaniem objęto 224 pacjentki, wśród nich 184 były w przedziale wieku ≥35–39 i 40...
Rola inhibitora aktywatora plazminogenu 1 (PAI-1) po menopauzie – wpływ terapii hormonalnej tego okresu
PAI-1 to ważny inhibitor w układzie fibrynolizy. W artykule przedstawiono związek tej glikoproteiny z chorobami układu krążenia, otyłością i nowotworami w grupie kobiet pomenopauzalnych. Podwyższony poziom PAI-1 po men...